ADA 2026 Takeaways

Research evidence excerpt

ADA 2026 Takeaways

Equity Research

Industry Update — June 8, 2026

Med Tech - Diabetes

Our Call Larry Biegelsen

Our ADA meetings reinforced four debates that should shape diabetes technology over Equity Analyst | Wells Fargo Securities, LLC

Lawrence.Biegelsen@wellsfargo.com | 212-214-8015

the next two years, including T2 NIT coverage expansion, ketone (dual-analyte) sensing,

Simran Kaurthe shift toward tubeless, and fully closed loop algorithms.

Equity Analyst | Wells Fargo Securities, LLC

SimranKaur@wellsfargo.com | 212-214-5973

DXCM's CONNECT T2NIT was stronger than expected and makes a compelling case Nathan Treybeck

for CMS coverage. The ~0.9% A1c advantage for CGM versus control handily beat our Equity Analyst | Wells Fargo Securities, LLC

0.5% bar and prior RCTs (DIAMOND, MOBILE). DXCM refiles with CMS this week, with a Nathan.Treybeck@wellsfargo.com | 212-214-8042

journal publication and guideline upgrade to follow. Our checks see it as strong enough Lei Huang

to support coverage without major caveats, a question of when, not if. Coverage is not Associate Equity Analyst | Wells Fargo Securities, LLC

needed for near-term growth but a key lever to sustain and accelerate beyond 10%. Lei.Huang@wellsfargo.com | 212-214-8039

Ketone sensing is the clearest new sensor battleground, a potential risk to DXCM if

priced at parity. ABT's Libre Duo, semi-unveiled at ADA, launches later this year, while

DXCM appears to be a few years behind and is prioritizing potassium and lactate first.

Physicians were enthusiastic, citing pediatrics as a key population, where DXCM likely

loses the most share, and SGLT2i T1 users (low % today). That said, adoption may be

tempered by clinical uncertainty on use and DXCM's brand loyalty.